One deal will see Philips' solution used to improve cancer patient outcomes while the other will beef up its ability to interpret data from oncology tests.
N-of-One will interpret data from HemeSeq profiles for acute myeloid leukemia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and other cancers.
N-of-One will provide treatment strategies and clinical trial opportunities for patients based on Inivata's ctDNA liquid biopsy test.
N-of-One will use the funds to develop new oncology clinical decision support solutions, and to expand its sales and marketing efforts.
N-of-One will identify the most relevant therapeutic options for each patient tested with Admera's 64-gene oncology panel.
N-of-One will provide Macrogen with clinical interpretation services for its clinical next-generation sequencing-based cancer panels.
N-of-One will provide clinical and scientific evidence that supports personalized treatment recommendations made on the basis of WuXi Nextcode's tumor-normal sequence interpretation.
N-of-One has launched a new service called PrecisionInsights through which it will provide clinical interpretation for small, targeted gene panels.
Under the terms of the agreement, N-of-One will provide clinical interpretation services for samples sequenced on a 50-gene hot-spot solid tumor panel.
N-of-One will provide clinical interpretation for GenomiCare's next-generation sequencing-based tumor exome profiling test in China.
A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.
Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.